Medipost to Participate in BIO KOREA... Showcasing Advanced Regenerative Medicine Technologies and Products
by Kwak Minjae
Published 28 Apr.2026 13:08(KST)
On-Site Meetings with Overseas Buyers and Global Partners
Global stem cell biotechnology company Medipost is participating in 'BIO KOREA 2026,' being held at COEX in Seoul from April 28 to April 30, to showcase its advanced regenerative medicine technologies and key products to both domestic and international audiences.
BIO KOREA is a leading international biohealth convention in Korea that has been held since 2006. The event serves as a platform to share the latest technologies and market trends in the global biohealth industry, while also expanding opportunities for collaboration among domestic and international companies, investors, and researchers.
Medipost is taking part as the operator of an exhibition booth within the 'Advanced Regenerative Medicine Pavilion,' which is jointly managed by the Council for Advanced Regenerative Medicine Industry (CARM), the Regenerative Medicine Promotion Foundation, and the Pan-Ministry Regenerative Medicine Technology Development Project Group, with support from the Ministry of Health and Welfare.
Through its participation, Medipost aims to promote its advanced regenerative medicine technologies and major products to global and domestic markets, while expanding exchanges with international biohealth companies and experts. The company also plans to explore new collaboration opportunities through on-site engagement with visitors and meetings with overseas buyers and global partners.
A Medipost representative stated, "BIO KOREA 2026 is an important platform where global biohealth industry stakeholders gather in one place," adding, "We will use this opportunity to highlight our technological competitiveness and seek out opportunities for global business expansion."
Meanwhile, in February of this year, Medipost received Investigational New Drug (IND) approval for the Phase 3 clinical trial of Cartistem in the United States. The company is conducting clinical development with the goal of enrolling the first patient (FPI) within the first half of the year. Medipost plans to obtain product approval and launch commercialization in the U.S. around 2031. In Japan, the Phase 3 clinical trial was completed in November last year, and the company plans to announce the results in the second quarter of this year and apply for product approval with the Pharmaceuticals and Medical Devices Agency (PMDA) by the end of the year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.